Krumax Pharmaceuticals Private Limited
About Krumax Pharmaceuticals Private Limited
Data last updated:
Krumax Pharmaceuticals Private Limited is a private limited company based in Ghaziabad, Uttar Pradesh, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 13 March 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U24110UP2019PTC114599.
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Ajay Kumar Kailash Narayan Gupta and Anjali Gupta.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at M – 286 F – 1 Sector – 12 Pratap Vihar, Ghaziabad, Uttar Pradesh, India – 201009.
As per the financials filed for FY 2025, the company reported a revenue of ₹25,000, a growth of 117% compared to the previous year. For the same year it recorded a net profit of ₹646 (net margin 2.6%) and EBITDA of ₹876 (EBITDA margin 3.5%). Revenue has declined at a compounded annual rate (CAGR) of 42% over three years.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressM – 286 F – 1 Sector – 12 Pratap Vihar, Ghaziabad, Uttar Pradesh, India – 201009
- IndustryChemicals, Manufacturing, Basic Chemical, Basic Chemicals Except Fertilizers And Nitrogen Compounds
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Krumax Pharmaceuticals Private Limited
The main business activity of Krumax Pharmaceuticals is hospital and medical care. In detail, this covers other hospital and medical care activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Krumax Pharmaceuticals Private Limited FY 2025 filings available
Krumax Pharmaceuticals Private Limited reported revenue of ₹25,000 (up 117% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Krumax Pharmaceuticals Private Limited
Revenue rose 117% in the latest year, though over three years it has declined at a compounded annual rate (CAGR) of 42%. EBITDA rose 84% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Krumax Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹876 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹646 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Krumax Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 2.6% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Krumax Pharmaceuticals are in the company report.
Financial statements from FY 2019
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Krumax Pharmaceuticals Private Limited
Krumax Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ajay Kumar Kailash Narayan Gupta | Director | 13 Mar 2019 | 7 Years 7 Months | Current |
| Anjali Gupta | Additional Director | 14 Jan 2022 | 4 Years 9 Months | Current |
Peer Comparison of Krumax Pharmaceuticals Private Limited
Krumax Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Prelude Pharmaceuticals Private Limited | ₹26,220 (FY 2024) | •••• | •••• | -11.0% | •••• | Allahabad, Uttar Pradesh, India |
| Fitbeing Pharmaceuticals Private Limited | ₹25,966 (FY 2023) | •••• | •••• | •••• | Etawah, Uttar Pradesh, India | |
| NKB Pharmaceuticals Private Limited | ₹25,753 (FY 2025) | •••• | •••• | -75.0% | •••• | Ballia, Uttar Pradesh, India |
| Apsy Pharmaceuticals Private Limited | ₹25,559 (FY 2024) | •••• | •••• | -28.0% | •••• | Jhansi, Uttar Pradesh, India |
| Paradise Pharmaceuticals Private Limited | ₹25,482 (FY 2020) | •••• | •••• | -18.0% | •••• | Mumbai, Maharashtra, India |
| Krumax Pharmaceuticals Private Limited this company | ₹25,000 (FY 2025) | •••• | •••• | 117.0% | •••• | Ghaziabad, Uttar Pradesh, India |
| NSN Pharmaceuticals Private Limited | ₹25,000 (FY 2025) | •••• | •••• | -29.0% | •••• | Agra, Uttar Pradesh, India |
| Ahantara Pharmaceuticals Private Limited | ₹24,859 (FY 2025) | •••• | •••• | •••• | Mohanlalganj, Uttar Pradesh, India | |
| Tirumala Surgical and Pharmaceuticals Private Limited | ₹24,710 (FY 2022) | •••• | •••• | •••• | Bhubaneswar, Odisha, India | |
| Mediscent Pharmaceuticals Private Limited | ₹24,500 (FY 2025) | •••• | •••• | -4.0% | •••• | Jankipuram Garden, Uttar Pradesh, India |
| John and Smith Pharmaceuticals Private Limited | ₹24,445 (FY 2018) | •••• | •••• | -97.0% | •••• | Muzaffarpur, Bihar, India |
Peers are the five companies nearest above and the five nearest below Krumax Pharmaceuticals by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Ownership and Shareholding of Krumax Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Krumax Pharmaceuticals Private Limited
Krumax Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Krumax Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Krumax Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Krumax Pharmaceuticals Private Limited
Krumax Pharmaceuticals Private Limited has 3 board changes on record since 2019: 2 appointments and 1 cessation. The latest: Anjali Gupta was appointed as Additional Director on 14 Jan 2022.
Credit Ratings, Litigation & Regulatory Alerts for Krumax Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Krumax Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Krumax Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Krumax Pharmaceuticals Private Limited
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Krumax Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Krumax Pharmaceuticals Private Limited
Krumax Pharmaceuticals is an active private limited company based in Ghaziabad, Uttar Pradesh, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 13 March 2019 (7+ years old) and is registered under CIN U24110UP2019PTC114599.
Krumax Pharmaceuticals reported revenue of ₹25,000 for FY 2025 (up 117% YoY).
Krumax Pharmaceuticals has 2 current directors:
- Ajay Kumar Kailash Narayan Gupta - Director
- Anjali Gupta - Additional Director
Krumax Pharmaceuticals reported a net profit of ₹646 (net margin 2.6%) and EBITDA of ₹876 (EBITDA margin 3.5%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Krumax Pharmaceuticals is -42% over three years. In the latest year (FY 2025) revenue rose 117%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Krumax Pharmaceuticals is U24110UP2019PTC114599. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Krumax Pharmaceuticals was incorporated on 13 March 2019, making it 7+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
The peers of Krumax Pharmaceuticals by revenue are Prelude Pharmaceuticals Private Limited, Fitbeing Pharmaceuticals Private Limited, NKB Pharmaceuticals Private Limited, Apsy Pharmaceuticals Private Limited, Paradise Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Anjali Gupta was appointed as Additional Director on 14 Jan 2022. Sachin Kumar Tiwari ceased to be Director on 14 Jan 2022. Ajay Kumar Kailash Narayan Gupta was appointed as Director on 13 Mar 2019.
The registered office of Krumax Pharmaceuticals is at M – 286 F – 1 Sector – 12 Pratap Vihar, Ghaziabad, Uttar Pradesh, India – 201009.
Krumax Pharmaceuticals has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1 Lakh.